美国国家癌症研究所李-佛美尼综合征队列基线筛查中癌症的患病率
该研究在美国国家癌症研究所对116例携带胚系TP53致病变异的李-佛美尼综合征患者(年龄≥3岁)进行基线多模态癌症筛查,发现8例(6.9%)癌症,其中7例仅需切除即可根治;40例(34.5%)需进一步检查,假阳性率为29.6%;非MRI技术未诊断出癌症。
要点
- 基线全身、脑及乳腺MRI可早期检出李-佛美尼综合征患者的 prevalent 癌症。
- 116例中8例(6.9%)检出癌症,7例仅需切除即可根治。
- 假阳性率为29.6%,40例(34.5%)需额外检查。
核心结论
- 基线全身、脑及乳腺MRI可在早期检出李-佛美尼综合征患者的 prevalent 癌症,该强化筛查方案可行。
研究设计与样本
- 前瞻性癌症筛查研究的基线评估,于2012年6月1日至2016年7月30日在美国国家癌症研究所(学术研究机构)进行。
- 纳入116例携带胚系TP53致病变异的李-佛美尼综合征患者,基线筛查时年龄≥3岁,且筛查前至少6个月未接受 active 癌症治疗。
主要发现
- 116例参与者中77例(66.4%)为女性,中位年龄37.6岁(范围3-68岁)。
- 基线筛查检出8例(6.9%)癌症:2例肺腺癌、1例骨肉瘤、1例肉瘤、1例星形细胞瘤、1例低级别胶质瘤、2例浸润前乳腺癌(导管原位癌)。
- 8例癌症中除1例外均仅需切除即可根治。
- 40例(34.5%)需额外检查以进一步评估筛查异常,其中32例为偶发、良性或正常发现,假阳性率为29.6%。
- 非MRI技术(包括基线血液检查、儿童腹部超声、乳腺X线摄影和结肠镜检查)在本队列中未导致 prevalent 癌症的诊断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Establishment of an optimal cancer surveillance program is important to reduce cancer-related morbidity and mortality in individuals with Li-Fraumeni syndrome, a rare, highly penetrant cancer predisposition syndrome. OBJECTIVE: To determine the feasibility and efficacy of a comprehensive cancer screening regimen in Li-Fraumeni syndrome, using multiple radiologic techniques, including rapid whole-body magnetic resonance imaging (MRI) and laboratory measurements. DESIGN, SETTING, AND PARTICIPANTS: Baseline evaluation of a prospective cancer screening study was conducted from June 1, 2012, to July 30, 2016, at the National Cancer Institute, National Institutes of Health (an academic research facility). Participants included 116 individuals with Li-Fraumeni syndrome with a germline TP53 pathogenic variant who were aged 3 years or older at the time of baseline screening and had not received active cancer therapy at least 6 months prior to screening. MAIN OUTCOMES AND MEASURES: Detection of prevalent cancer with multimodal screening techniques and the need for additional evaluation. RESULTS: Of the 116 study participants, 77 (66.4%) were female; median age was 37.6 years (range, 3-68 years). Baseline cancer screening led to the diagnosis of cancer in 8 (6.9%) individuals (2 lung adenocarcinomas, 1 osteosarcoma, 1 sarcoma, 1 astrocytoma, 1 low-grade glioma, and 2 preinvasive breast cancers [ductal carcinoma in situ]); all but 1 required only resection for definitive treatment. A total of 40 (34.5%) participants required additional studies to further investigate abnormalities identified on screening, with 32 having incidental, benign, or normal findings, resulting in a false-positive rate of 29.6%. Non-MRI techniques, including baseline blood tests, abdominal ultrasonography in children, mammography, and colonoscopy, did not lead to a diagnosis of prevalent cancer in our cohort. CONCLUSIONS AND RELEVANCE: This study describes the establishment and feasibility of an intensive cancer surveillance protocol for individuals with Li-Fraumeni syndrome. Prevalent cancers were detected at an early stage with baseline whole-body, brain, and breast MRI. Prospective screening of the participants is under way.
引用
- Mai PL, Khincha PP, Loud JT, et al. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort. JAMA Oncol. 2017. PMID: 28772286. doi:10.1001/jamaoncol.2017.1350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。